Sreesha P Srinivasa
Overview
Explore the profile of Sreesha P Srinivasa including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
5
Citations
50
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Jungholm O, Trkulja C, Moche M, Srinivasa S, Christakopoulou M, Davidson M, et al.
Sci Rep
. 2024 Aug;
14(1):19656.
PMID: 39179604
KRAS belongs to a family of small GTPases that act as binary switches upstream of several signalling cascades, controlling proliferation and survival of cells. Mutations in KRAS drive oncogenesis, especially...
2.
Trkulja C, Jungholm O, Davidson M, Jardemark K, Marcus M, Hagglund J, et al.
Sci Adv
. 2021 Apr;
7(16).
PMID: 33863724
Several important drug targets, e.g., ion channels and G protein-coupled receptors, are extremely difficult to approach with current antibody technologies. To address these targets classes, we explored kinetically controlled proteases...
3.
Eliades P, Miller D, Miao B, Kumar R, Taylor M, Buch S, et al.
Cancer Biol Ther
. 2016 Jan;
17(7):778-84.
PMID: 26810603
Nearly 100% of melanomas have a defect in the p16(INK4A):cyclin D-CDK4/6:RB pathway, leading to abnormal cell cycle control and unregulated cellular proliferation. Here, we report that P1446A-05, a novel multi-CDK...
4.
Paiva C, Godbersen J, Soderquist R, Rowland T, Kilmarx S, Spurgeon S, et al.
PLoS One
. 2015 Nov;
10(11):e0143685.
PMID: 26606677
CDK (cyclin-dependent kinase) inhibitors have shown remarkable activity in CLL, where its efficacy has been linked to inhibition of the transcriptional CDKs (7 and 9) and deregulation of RNA polymerase...
5.
Lee N, Lira M, Pavlicek A, Ye J, Buckman D, Bagrodia S, et al.
PLoS One
. 2012 Jun;
7(6):e39653.
PMID: 22745804
Targeting cancers with amplified or abnormally activated c-Met (hepatocyte growth factor receptor) may have therapeutic benefit based on nonclinical and emerging clinical findings. However, the eventual emergence of drug resistant...